Inventiva S.A. ADR (IVA) Social Stream
Featured Post From StockTwits About IVA
$IVA, a company developing Lanifibranor, a drug addressing Nonalcoholic steatohepatitis (NASH), will present the P2B data on June 25th at the EASL International Liver Congress.Tain0os, published June 17, 2021
The stock has been range bound between +3 & -1Σ. The company topped at $19 last January, but has not broken its upward momentum. We have bounced off -1Σ and completed the x̄ reversal.
Due to a lack of volume, the TTM is kind of irrelevant. Nevertheless, there's been some crowd loading in the $12-16/share zone per volume profile.
This company has a float of 10.29M (not sure if FINVIZ data is up to date) with 150k shares being held short.
IMPORTANT: there are a whole bunch of 6-k filings on EDGAR. The management is diluting. That being said, the float remains significantly small that a MASSIVE move like ORPH is possible.
A swing long towards +2Σ or +3Σ gives us $4-$6 upside potential: